Loading...
Loading...
IGMS| Name | Value |
|---|---|
| Revenues | 143.6M |
| Cost of Revenue | 0.4M |
| Gross Profit | 143.2M |
| Operating Expense | 12.9M |
| Operating I/L | 130.3M |
| Other Income/Expense | -32.7M |
| Interest Income | 1.3M |
| Pretax | 97.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 97.6M |
IGM Biosciences, Inc. is a biotechnology company specializing in the development of Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate, IGM-2323, is a bispecific IgM antibody in Phase 2 clinical trials for relapsed/refractory B cell Non-Hodgkin's lymphoma. Additionally, it is developing several other IgM antibodies targeting various cancers and hematologic malignancies. IGM Biosciences has a collaboration and license agreement with Genzyme Corporation for the generation, development, manufacture, and commercialization of IgM antibodies.
